SCHEDULE: CVI Investments Amends Galmed Pharma Stake to 3.1%
Amendment to Beneficial Ownership Statement
CVI Investments, Inc. and Heights Capital Management, Inc. have filed an amendment to their beneficial ownership of Galmed Pharmaceuticals Ltd., reporting a 3.1% stake.
Summary
- CVI Investments, Inc. and its investment manager, Heights Capital Management, Inc., reported beneficial ownership of 173,333 ordinary shares of Galmed Pharmaceuticals Ltd.
- This represents 3.1% of the company's ordinary shares outstanding.
- The shares are issuable upon the exercise of warrants, which are subject to a 9.99% beneficial ownership limitation.
- The filing is an Amendment No. 4 to a Schedule 13G.
- Galmed Pharmaceuticals Ltd. had 5,479,231 ordinary shares outstanding as of September 17, 2025, according to a Form 6-K filed on September 19, 2025.
Sentiment
Score: 5
Explanation: The filing is a routine disclosure of beneficial ownership. While a 3.1% stake is not insignificant, it is below the 5% threshold for initial Schedule 13G filings, and as an amendment, it could imply a reduction in stake, which is a neutral to slightly negative signal. However, the filing itself is purely factual and does not contain performance or forward-looking statements from the issuer.
Positives
- Continued institutional investment by CVI Investments, Inc. and Heights Capital Management, Inc. in Galmed Pharmaceuticals Ltd.
Negatives
- The reported beneficial ownership of 3.1% is below the 5% threshold typically associated with initial Schedule 13G filings, potentially suggesting a reduction in stake from previous filings.
Future Outlook
NA
Management Comments
- The securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, nor in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.
Industry Context
NA
Stakeholder Impact
- Shareholders: Provides transparency regarding institutional ownership, potentially indicating a reduction in a significant institutional stake if the 3.1% represents a decrease from previous filings.
Key Dates
| Date | Description |
|---|---|
| 2025-09-17 | Date as of which 5,479,231 shares of Galmed Pharmaceuticals Ltd. were outstanding, according to a Form 6-K filed on September 19, 2025. |
| 2025-09-19 | Date of filing of the Company's Report of Foreign Private Issuer on Form 6-K, which indicated shares outstanding. |
| 2025-09-30 | Date of event which required the filing of this Schedule 13G Amendment No. 4. |
| 2025-11-06 | Date of signature for the Schedule 13G Amendment No. 4 filing. |
Keywords
Galmed Pharmaceuticals, CVI Investments, Heights Capital Management, Beneficial Ownership, Schedule 13G, Warrants, Biotechnology, Pharmaceuticals, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.